Overview
Shennon Biotechnologies develops precision immunotherapies for solid tumors, focusing on T-cell engagers (TCEs). Its discovery platform combines target discovery, ultra-high-throughput microfluidic screening, computational design, and safety prediction, with the TCELERATOR system profiling over 10 million single-cell interactions. It differentiates itself by integrating large-scale functional screening with multi-target TCE formats (trispecific, antibody-based, and TCR-based) to identify safer, more effective candidates for solid tumors. The company aims to move from platform development to development-stage execution, advancing three programs (SBT-121, SBT-201, SBT-425) and pursuing ongoing fundraising and leadership to push toward clinical development.
Work here?Claim your company
Simplify's take
What believers are saying
- September 2026 financing added $12 million and lifted total funding to $25 million.
- Cyril Konto became CEO in August 2026, adding late-stage oncology execution experience.
- Management says it plans an IND candidate within two years and potential pharma partnerships.
What critics are saying
- Shennon has no clinical data yet, so 2027 IND failure would crush valuation.
- Solid-tumor TCEs face toxicity and efficacy traps; one bad safety signal kills programs.
- Only $25 million funds three programs and platform buildout, leaving brutal dilution risk.
What makes Shennon Biotechnologies unique
- TCELERATOR profiles over 10 million single-cell interactions per experiment, accelerating TCE discovery.
- Shennon blends microfluidics, computational design, and AI safety prediction in one discovery stack.
- Its pipeline spans antibody and TCR T-cell engagers for lung, ovarian, and liver cancers.
Help us improve and share your feedback! Did you find this helpful?